Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 12.24 Million USD | 10.85% |
| 2022 | 11.04 Million USD | 52.77% |
| 2021 | 7.23 Million USD | 282.74% |
| 2020 | 1.88 Million USD | 109.3% |
| 2019 | 902.93 Thousand USD | -4.16% |
| 2018 | 942.15 Thousand USD | 115.42% |
| 2017 | 437.34 Thousand USD | 210.11% |
| 2016 | 141.02 Thousand USD | 25.01% |
| 2015 | 112.81 Thousand USD | -31.46% |
| 2014 | 164.58 Thousand USD | -36.79% |
| 2013 | 260.35 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 72.91 Thousand USD | -97.57% |
| 2024 Q1 | 2.99 Million USD | 2.17% |
| 2023 Q3 | 3.33 Million USD | 19.62% |
| 2023 FY | 12.24 Million USD | 10.85% |
| 2023 Q1 | 3.18 Million USD | 16.85% |
| 2023 Q2 | 2.78 Million USD | -12.43% |
| 2023 Q4 | 2.93 Million USD | -12.03% |
| 2022 Q2 | 3.27 Million USD | 37.35% |
| 2022 Q1 | 2.38 Million USD | -9.24% |
| 2022 FY | 11.04 Million USD | 52.77% |
| 2022 Q4 | 2.72 Million USD | 2.36% |
| 2022 Q3 | 2.66 Million USD | -18.68% |
| 2021 FY | 7.23 Million USD | 282.74% |
| 2021 Q2 | 1.22 Million USD | 424.53% |
| 2021 Q1 | 233.29 Thousand USD | 16.63% |
| 2021 Q3 | 3.14 Million USD | 157.3% |
| 2021 Q4 | 2.62 Million USD | -16.55% |
| 2020 Q1 | 245.72 Thousand USD | 3.13% |
| 2020 Q3 | 253.18 Thousand USD | -78.74% |
| 2020 Q4 | 200.02 Thousand USD | -21.0% |
| 2020 FY | 1.88 Million USD | 109.3% |
| 2020 Q2 | 1.19 Million USD | 384.66% |
| 2019 Q2 | 260.97 Thousand USD | 7.6% |
| 2019 Q3 | 161.16 Thousand USD | -38.25% |
| 2019 Q4 | 238.26 Thousand USD | 47.84% |
| 2019 FY | 902.93 Thousand USD | -4.16% |
| 2019 Q1 | 242.53 Thousand USD | 3.6% |
| 2018 Q4 | 234.1 Thousand USD | -20.43% |
| 2018 Q3 | 294.23 Thousand USD | 33.27% |
| 2018 Q2 | 220.77 Thousand USD | 14.37% |
| 2018 Q1 | 193.04 Thousand USD | -25.39% |
| 2018 FY | 942.15 Thousand USD | 115.42% |
| 2017 FY | 437.34 Thousand USD | 210.11% |
| 2017 Q4 | 258.73 Thousand USD | 312.68% |
| 2017 Q3 | 62.69 Thousand USD | 4.54% |
| 2017 Q2 | 59.97 Thousand USD | 7.21% |
| 2017 Q1 | 55.94 Thousand USD | 14.55% |
| 2016 Q1 | 29.13 Thousand USD | 12.02% |
| 2016 FY | 141.02 Thousand USD | 25.01% |
| 2016 Q4 | 48.83 Thousand USD | 45.01% |
| 2016 Q3 | 33.67 Thousand USD | 14.61% |
| 2016 Q2 | 29.38 Thousand USD | 0.86% |
| 2015 FY | 112.81 Thousand USD | -31.46% |
| 2015 Q3 | 27.03 Thousand USD | -9.51% |
| 2015 Q2 | 29.88 Thousand USD | -0.0% |
| 2015 Q1 | 29.88 Thousand USD | -6.4% |
| 2015 Q4 | 26 Thousand USD | -3.81% |
| 2014 Q4 | 31.92 Thousand USD | 0.0% |
| 2014 FY | 164.58 Thousand USD | -36.79% |
| 2013 FY | 260.35 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 97.839% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -535.135% |
| Embecta Corp. | 1.12 Billion USD | 98.907% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 98.185% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 49.161% |
| SCYNEXIS, Inc. | 140.14 Million USD | 91.26% |
| Journey Medical Corporation | 79.18 Million USD | 84.531% |
| Safety Shot Inc | 202.67 Thousand USD | -5943.593% |
| Alpha Teknova, Inc. | 36.68 Million USD | 66.611% |
| Bright Green Corporation | 401.49 Thousand USD | -2950.766% |
| Procaps Group, S.A. | 409.92 Million USD | 97.012% |
| Alvotech | 91.43 Million USD | 86.604% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 97.484% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 75.785% |
| Cosmos Health Inc. | 53.37 Million USD | 77.053% |
| Dynavax Technologies Corporation | 232.28 Million USD | 94.727% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 89.471% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 97.362% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 49.161% |
| Theratechnologies Inc. | 81.76 Million USD | 85.02% |
| Harrow Health, Inc. | 130.19 Million USD | 90.592% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 3.82% |
| Biofrontera Inc. | 34.07 Million USD | 64.05% |
| DURECT Corporation | 8.54 Million USD | -43.291% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 97.984% |
| Cronos Group Inc. | 88.84 Million USD | 86.213% |
| OptiNose, Inc. | 70.98 Million USD | 82.745% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 97.233% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -88.058% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 97.172% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 69.032% |
| Radius Health, Inc. | 2.88 Billion USD | 99.575% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 62.089% |
| ProPhase Labs, Inc. | 44.38 Million USD | 72.403% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 98.796% |
| Procaps Group S.A. | 409.92 Million USD | 97.012% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -840.749% |
| Viatris Inc. | 15.42 Billion USD | 99.921% |
| Rockwell Medical, Inc. | 83.61 Million USD | 85.351% |
| Aytu BioPharma, Inc. | 81 Million USD | 84.879% |
| SIGA Technologies, Inc. | 139.91 Million USD | 91.246% |
| Tilray Brands, Inc. | 788.94 Million USD | 98.447% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 90.45% |
| Shineco, Inc. | 9.8 Million USD | -24.962% |
| PetIQ, Inc. | 1.1 Billion USD | 98.888% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -101971.25% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.351% |
| Alimera Sciences, Inc. | 80.75 Million USD | 84.832% |
| Silver Spike Investment Corp. | 11.72 Million USD | -4.491% |
| Assertio Holdings, Inc. | 152.06 Million USD | 91.945% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -110.37% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | 29.675% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -1037.913% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 56.197% |
| Hempacco Co., Inc. | 4.04 Million USD | -202.759% |
| Talphera, Inc. | 651 Thousand USD | -1781.498% |
| Alvotech | 91.43 Million USD | 86.604% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 96.131% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.055% |
| Currenc Group, Inc. | 53.25 Million USD | 77.0% |
| Kamada Ltd. | 144.75 Million USD | 91.539% |
| Indivior PLC | 1.09 Billion USD | 98.879% |
| Evoke Pharma, Inc. | 5.18 Million USD | -136.43% |
| Flora Growth Corp. | 76.07 Million USD | 83.899% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -1037.913% |
| Evolus, Inc. | 202.08 Million USD | 93.939% |
| HUTCHMED (China) Limited | 837.99 Million USD | 98.538% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 98.099% |
| Akanda Corp. | 2.16 Million USD | -467.049% |